Section Arrow
VCEL.NASDAQ
- Vericel Corp
Quotes are at least 15-min delayed:2026/08/31 17:09 EDT
After Hours
Last
 39.901436
+0.001436 (0.00%)
Bid
30.07
Ask
49.75
High 39.907182 
Low 39.8972 
Volume 25.21K 
Regular Hours (Closed)
Last
 39.9
-1.05 (-2.56%)
Day High 
40.8808 
Prev. Close
40.95 
1-M High
49.32 
Volume 
636.30K 
Bid
30.07
Ask
49.75
Day Low
39.34 
Open
40.48 
1-M Low
40.5094 
Market Cap 
2.10B 
Currency 美元 
P/E 85.31 
%Yield -- 
10-SMA 42.63 
20-SMA 43.78 
50-SMA 44.77 
52-W High 49.32 
52-W Low 28.95 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.48/0.80
Enterprise Value
2.18B
Balance Sheet
Book Value Per Share
7.23
Cash Flow
Cash Flow Yield
0.03
Income Statement
Total Revenue
--
Operating Revenue Per Share
3.62
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CLGNCollPlant Biotechnologies Ltd0.3879+0.0299+8.35%-- 
After Hours 0.3641 -0.0238 -6.14%
AIMAIM ImmunoTech Inc.0.226-0.0324-12.54%-- 
After Hours 0.23169 +0.00569 +2.52%
ROIVRoivant Sciences Ltd34.64-0.07-0.20%-- 
After Hours 35.8942 +1.2542 +3.62%
CVKDCadrenal Therapeutics Inc1.75+0.21+13.64%-- 
After Hours 1.6 -0.15 -8.57%
MRNAModerna140.34+2.35+1.70%-- 
After Hours 139.0767 -1.2633 -0.90%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.